These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 794728)

  • 1. Use of narcotic antagonists (naltrexone) in an addiction treatment program.
    Lewis D; Hersch R; Black R; Mayer J
    NIDA Res Monogr; 1976 Sep; (9):99-105. PubMed ID: 794728
    [No Abstract]   [Full Text] [Related]  

  • 2. Varying clinical contexts for administering naltrexone.
    Hurzeler M; Gerwirtz D; Kleber H
    NIDA Res Monogr; 1976 Sep; (9):48-66. PubMed ID: 794721
    [No Abstract]   [Full Text] [Related]  

  • 3. An analysis of naltrexone use--its efficacy, safety and potential.
    Landsberg R; Taintor Z; Plumb M; Amico L; Wicks N
    NIDA Res Monogr; 1976 Sep; (9):106-13. PubMed ID: 1004529
    [No Abstract]   [Full Text] [Related]  

  • 4. Narcotic antagonist treatment of the criminal justice patient-institutional vs outpatient-including a 24 hour detox naltrexone induction regimen with oral medication.
    Brahen L; Wiechert V; Capone T
    NIDA Res Monogr; 1976 Sep; (9):93-8. PubMed ID: 794727
    [No Abstract]   [Full Text] [Related]  

  • 5. Patient response to naltrexone: issues of acceptance, treatment effects, and frequency of administration.
    Curran S; Savage C
    NIDA Res Monogr; 1976 Sep; (9):67-9. PubMed ID: 794722
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical experience with naltrexone in a behavioral research study: an interim report.
    Greenstein R; O'Brien C; Mintz J; Woody G; Hanna N
    NIDA Res Monogr; 1976 Sep; (9):141-9. PubMed ID: 794715
    [No Abstract]   [Full Text] [Related]  

  • 7. Narcotic antagonist treatment: clinical experience with naltrexone.
    Lewis DC; Mayer J; Hersch RG; Black R
    Int J Addict; 1978 Aug; 13(6):961-73. PubMed ID: 730406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical experiences with naltrexone in 370 detoxified addicts.
    Thomas M; Kauders F; Harris M; Cooperstein J; Hough G; Resnick R
    NIDA Res Monogr; 1976 Sep; (9):88-92. PubMed ID: 794726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of the National Institute on Drug Abuse in the development of naltrexone.
    Ginzburg HM; Glass WJ
    J Clin Psychiatry; 1984 Sep; 45(9 Pt 2):4-6. PubMed ID: 6088469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comments and findings from a naltrexone double blind study.
    Keegan J; Lavenduski C; Schooff K
    NIDA Res Monogr; 1976 Sep; (9):74-6. PubMed ID: 794724
    [No Abstract]   [Full Text] [Related]  

  • 11. The development of sustained action preparations of narcotic antagonists.
    Willette RE
    NIDA Res Monogr; 1978; (19):333-9. PubMed ID: 218109
    [No Abstract]   [Full Text] [Related]  

  • 12. Narcotic antagonists: naltrexone progress report: introduction.
    Renault PF
    NIDA Res Monogr; 1976 Sep; (9):1-3. PubMed ID: 794713
    [No Abstract]   [Full Text] [Related]  

  • 13. NIDA's naltrexone research program.
    Julius D
    NIDA Res Monogr; 1976 Sep; (9):5-11. PubMed ID: 187943
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical evaluation of naltrexone treatment of opiate-dependent individuals. Report of the National Research Council Committee on Clinical Evaluation of Narcotic Antagonists.
    Arch Gen Psychiatry; 1978 Mar; 35(3):335-40. PubMed ID: 365122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors influencing success in an antagonistic treatment program.
    Parwatikar S; Crawford J; Nelkupa JV; De Gracia C
    NIDA Res Monogr; 1976 Sep; (9):77-81. PubMed ID: 794725
    [No Abstract]   [Full Text] [Related]  

  • 16. Naltrexone in a behavioral treatment program.
    O'Brien C; Greenstein R
    NIDA Res Monogr; 1976 Sep; (9):136-40. PubMed ID: 63915
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical outcome with naltrexone.
    Resnick RB; Washton AM
    Ann N Y Acad Sci; 1978; 311():241-7. PubMed ID: 283722
    [No Abstract]   [Full Text] [Related]  

  • 18. Development of injectable microcapsules for use in the treatment of narcotic addiction.
    Thies C
    Natl Inst Drug Abuse Res Monogr Ser; 1975; (4):19-20. PubMed ID: 1241971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Philosophy and status of NAS CENA study.
    Hollister LE
    NIDA Res Monogr; 1976 Sep; (9):45-7. PubMed ID: 794720
    [No Abstract]   [Full Text] [Related]  

  • 20. Naloxone-precipitated withdrawal: a method for rapid induction onto naltrexone.
    Resnick RB; Kestenbaum RS; Washton A; Poole D
    Clin Pharmacol Ther; 1977 Apr; 21(4):409-13. PubMed ID: 849672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.